Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
| Small Cap
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
N/A
Industry Median
N/A
Market Cap Median
N/A
P/B RATIO
N/A
Industry Median
N/A
Market Cap Median
N/A
P/S RATIO
N/A
Industry Median
N/A
Market Cap Median
N/A
Others
PEG RATIO
N/A
EV/EBITDA RATIO
N/A
Revenue GrowthAverageEBITDA GrowthAverageEPS GrowthAverageRevenue Growth
EBITDA Growth
EPS Growth
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 18 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤4th May 26
Q4 and FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤27th Apr 26
Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
Concall Report⬤27th Jan 26
Q3 and nine months FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤21st Jan 26
Quarterly Financial Results Q3 FY 2025–26
NEUTRAL SENTIMENT
Jagsonpal Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a wide range of pharmaceutical formulations. It focuses on therapeutic areas like gynaecology, orthopaedics, pain management, anti-infectives, and general medicine, catering to both domestic and international markets, positioning itself as a diversified healthcare provider.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Jagsonpal Pharmaceuticals Ltd's P/E ratio (TTM) is N/A, compared to the industry median of 32.40 and large cap median of 39.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Jagsonpal Pharmaceuticals Ltd's P/B ratio is N/A, compared to the industry median of 4.13 and large cap median of N/A.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Jagsonpal Pharmaceuticals Ltd's P/S ratio is 3.03, compared to the industry median of 3.33 and large cap median of N/A.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Jagsonpal Pharmaceuticals Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Jagsonpal Pharmaceuticals Ltd's EV/EBITDA ratio is 10.03.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Jagsonpal Pharmaceuticals Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Jagsonpal Pharmaceuticals Ltd's ROA is N/A.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Jagsonpal Pharmaceuticals Ltd's ROCE is N/A.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Jagsonpal Pharmaceuticals Ltd's operating margin is N/A.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Jagsonpal Pharmaceuticals Ltd's net margin is N/A.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Jagsonpal Pharmaceuticals Ltd's current ratio is N/A.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Jagsonpal Pharmaceuticals Ltd's debt-to-equity ratio is N/A.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Jagsonpal Pharmaceuticals Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Jagsonpal Pharmaceuticals Ltd's DPS is ₹2.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Jagsonpal Pharmaceuticals Ltd's EPS is N/A.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹N/A. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1964
Headquarters: New Delhi, Delhi
Core Offerings: Gynaecology, Orthopaedics, Pain Management, Anti-infectives, General Medicine
Stock Listing: NSE (JAGSNPHARM), BSE (507789)
Promoter: Chopra family
Founded in 1964, Jagsonpal Pharmaceuticals Ltd began its journey to establish a presence in the Indian pharmaceutical sector. Over the decades, the company has expanded its product portfolio and manufacturing capabilities, developing a strong focus on various therapeutic segments. It has consistently worked on strengthening its domestic and international market reach through a robust distribution network.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Gynaecology | Not disclosed | Operating Profit |
| Orthopaedics & Pain Management | Not disclosed | Operating Profit |
| Anti-infectives & General Medicine | Not disclosed | Operating Profit |
| Dermatology | Not disclosed | Operating Profit |
Gynaecology: Offers solutions for women's health, including fertility, hormonal disorders, and contraception.
Orthopaedics & Pain Management: Provides medications for bone health, inflammation, and various types of pain management.
Anti-infectives & General Medicine: Includes antibiotics and drugs for common ailments and infectious diseases.
Dermatology: Caters to skin conditions with a range of topical and oral formulations.
Sandeep Chopra - Managing Director. Mr. Sandeep Chopra leads the company's operations and strategic initiatives, driving growth and market expansion for Jagsonpal Pharmaceuticals Ltd.
No major subsidiaries reported.
Bonus Issue: 1:1 ratio on December 06, 2022.
The Jagsonpal Pharmaceuticals Ltd share price today is ₹N/A on NSE (JAGSNPHARM), as of 26 Sept 2026.
As of 26 Sept 2026, Jagsonpal Pharmaceuticals Ltd share price is ₹N/A, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Jagsonpal Pharmaceuticals Ltd's market cap is ₹N/A crore (Small Cap).
Jagsonpal Pharmaceuticals Ltd's current P/E ratio is N/A, compared to the Financial Services sector average of 39.
Jagsonpal Pharmaceuticals Ltd's current P/B ratio is N/A.
Jagsonpal Pharmaceuticals Ltd's current dividend yield is N/A. Last dividend of ₹2.00 per share was declared on 16-Aug-2023.
Jagsonpal Pharmaceuticals Ltd's EPS (TTM) is ₹N/A.
Jagsonpal Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a wide range of pharmaceutical formulations. It focuses on therapeutic areas like gynaecology, orthopaedics, pain management, anti-infectives, and general medicine, catering to both domestic and international markets, positioning itself as a diversified healthcare provider.
Jagsonpal Pharmaceuticals Ltd is promoted by Chopra family, holding N/A as of 26 Sept 2026.
Jagsonpal Pharmaceuticals Ltd is listed on NSE (JAGSNPHARM) and BSE (507789). Its next quarterly results are expected on August 2024.
Financial Performance & Growth
Capital Efficiency & Returns
Shareholding & Ownership Structure
